Gene-Therapy Stocks Get Boost as Analysts Speculate Novartis' Next Target -- Market Mover
April 09 2018 - 12:59PM
Dow Jones News
Gene-therapy companies got a boost during Monday trading after
Novartis AG's (NVS) $8.7 billion deal to buy AveXis Inc. (AVXS),
making good on CEO Vasant Narasimhan's promise to strike deals to
refocus the company. Analysts at Chardan said Regenxbio Inc.
(RGNX), Spark Therapeutics Inc. (ONCE) and Nightstar Therapeutics
PLC (NITE) could be among the company's next targets. Regenxbio
shares jumped 22% to $33.05 during Monday trading, while Spark
shares rose 14% to $70.75 and rand Nightstar rose 8.1% to $12.65.
(imani.moise@wsj.com; @moisenoise)
(END) Dow Jones Newswires
April 09, 2018 12:44 ET (16:44 GMT)
Copyright (c) 2018 Dow Jones & Company, Inc.
Novartis (NYSE:NVS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Novartis (NYSE:NVS)
Historical Stock Chart
From Apr 2023 to Apr 2024
